{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:46:43Z","timestamp":1779893203826,"version":"3.53.1"},"reference-count":56,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of General Medical Sciences of the National Institutes","award":["P20GM125503"],"award-info":[{"award-number":["P20GM125503"]}]},{"name":"National Institute of Health","award":["1R21 OD026618"],"award-info":[{"award-number":["1R21 OD026618"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multiple myeloma (MM) is a plasma cell malignancy that causes an accumulation of terminally differentiated monoclonal plasma cells in the bone marrow, accompanied by multiple myeloma bone disease (MMBD). MM animal models have been developed and enable to interrogate the mechanism of MM tumorigenesis. However, these models demonstrate little or no evidence of MMBD. We try to establish the MMBD model with severe bone lesions and easily accessible MM progression. 1 \u00d7 106 luciferase-expressing 5TGM1 cells were injected into 8\u201312 week-old NOD SCID gamma mouse (NSG) and C57BL\/KaLwRij mouse via the tail vein. Myeloma progression was assessed weekly via in vivo bioluminescence (BL) imaging using IVIS-200. The spine and femur\/tibia were extracted and scanned by the micro-computer tomography for bone histo-morphometric analyses at the postmortem. The median survivals were 56 days in NSG while 44.5 days in C57BL\/KaLwRij agreed with the BL imaging results. Histomorphic and DEXA analyses demonstrated that NSG mice have severe bone resorption that occurred at the lumbar spine but no significance at the femur compared to C57BL\/KaLwRij mice. Based on these, we conclude that the systemic 5TGM1 injected NSG mouse slowly progresses myeloma and develops more severe MMBD than the C57BL\/KaLwRij model.<\/jats:p>","DOI":"10.3390\/cancers13174277","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:19:26Z","timestamp":1629937166000},"page":"4277","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Improved Animal Model of Multiple Myeloma Bone Disease"],"prefix":"10.3390","volume":"13","author":[{"given":"Syed Hassan","family":"Mehdi","sequence":"first","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A","family":"Morris","sequence":"additional","affiliation":[{"name":"Graduate Program in Interdisciplinary Biomedical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Ae","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA 01605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghoon","family":"Yoon","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"},{"name":"Graduate Program in Interdisciplinary Biomedical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"ref_1","unstructured":"National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program (2021, July 30). Cancer Stat Facts: Myeloma, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2010.08.001","article-title":"Adhesive interactions: The multi\u2013task biochemical toolbox of cancer cells","volume":"20","author":"Katz","year":"2010","journal-title":"Semin. Cancer. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2016.02.019","article-title":"The effects of proteasome inhibitors on bone remodeling in multiple myeloma","volume":"86","author":"Zangari","year":"2016","journal-title":"Bone"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo. Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00223-017-0351-7","article-title":"New agents in the treatment of myeloma bone disease","volume":"102","author":"Ring","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: Pathophysiology and management","volume":"2","author":"Silbermann","year":"2013","journal-title":"J. Bone. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: From biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/35046196","article-title":"Bone versus immune system","volume":"408","author":"Arron","year":"2000","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.18632\/oncotarget.27439","article-title":"Immune system and bone microenvironment: Rationale for targeted cancer therapies","volume":"11","author":"Gnoni","year":"2020","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"640954","DOI":"10.3389\/fgene.2021.640954","article-title":"Animal Models of Multiple Myeloma Bone Disease","volume":"12","author":"Mehdi","year":"2021","journal-title":"Front. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.thj.6200052","article-title":"The 5TMM series: A useful in vivo mouse model of human multiple myeloma","volume":"1","author":"Asosingh","year":"2000","journal-title":"Hematol. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S8756-3282(97)00056-2","article-title":"A murine model of human myeloma bone disease","volume":"20","author":"Garrett","year":"1997","journal-title":"Bone"},{"key":"ref_14","first-page":"91","article-title":"Animal model of human disease. Benign monoclonal gammopathy (idiopathic paraproteinemia)","volume":"105","author":"Radl","year":"1981","journal-title":"Am. J. Pathol."},{"key":"ref_15","first-page":"593","article-title":"Animal model of human disease. Multiple myeloma","volume":"132","author":"Radl","year":"1988","journal-title":"Am. J. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4049\/jimmunol.122.2.609","article-title":"Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL\/KaLwRij mice","volume":"122","author":"Radl","year":"1979","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bone.2013.12.025","article-title":"Parathyroid hormone receptor mediates the anti\u2013myeloma effect of proteasome inhibitors","volume":"61","author":"Zangari","year":"2014","journal-title":"Bone"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1210\/en.2017-03083","article-title":"Thymic PTH Increases After Thyroparathyroidectomy in C57BL\/KaLwRij Mice","volume":"159","author":"Zangari","year":"2018","journal-title":"Endocrinology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jbo.2018.02.005","article-title":"Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo","volume":"12","author":"Zangari","year":"2018","journal-title":"J. Bone Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma","volume":"76","author":"Anderson","year":"2016","journal-title":"Cancer. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2004-01-0236","article-title":"Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis","volume":"104","author":"Mori","year":"2004","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Fryer, R.A., Graham, T.J., Smith, E.M., Walker-Samuel, S., Morgan, G.J., Robinson, S.P., and Davies, F.E. (2013). Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057641"},{"key":"ref_23","first-page":"6689","article-title":"Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID\/NOD in vivo model: Biologic and clinical implications","volume":"63","author":"Mitsiades","year":"2003","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V92.8.2908","article-title":"Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations","volume":"92","author":"Yaccoby","year":"1998","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1182\/blood.V94.10.3576.422k01_3576_3582","article-title":"The proliferative potential of myeloma plasma cells manifest in the SCID-hu host","volume":"94","author":"Yaccoby","year":"1999","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2002-03-0939","article-title":"Antimyeloma efficacy of thalidomide in the SCID-hu model","volume":"100","author":"Yaccoby","year":"2002","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","article-title":"The SCID\u2013rab model: A novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells","volume":"18","author":"Yata","year":"2004","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.bbmt.2012.04.004","article-title":"Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus","volume":"18","author":"Bartee","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3324\/haematol.2011.054254","article-title":"Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model","volume":"97","author":"Swift","year":"2012","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2119\/molmed.2011.00178","article-title":"Therapeutic potential of SH2 domain-containing inositol\u20135\u2019\u2013phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer","volume":"18","author":"Fuhler","year":"2012","journal-title":"Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/bjh.12226","article-title":"Potent in vitro and in vivo activity of sorafenib in multiple myeloma: Induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization","volume":"161","author":"Udi","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1517\/14712598.2013.799131","article-title":"Preclinical models of multiple myeloma: A critical appraisal","volume":"13","author":"Schuler","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbrc.2003.11.120","article-title":"Establishment of a new model of human multiple myeloma using NOD\/SCID\/gammac(null) (NOG) mice","volume":"313","author":"Miyakawa","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects","volume":"27","author":"Hurchla","year":"2013","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf\u20131 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/leu.2010.173","article-title":"The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"20119","DOI":"10.18632\/oncotarget.24614","article-title":"Mouse models of multiple myeloma: Technologic platforms and perspectives","volume":"9","author":"Rossi","year":"2018","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1158\/0008-5472.CAN-06-3699","article-title":"A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma","volume":"67","author":"Boylan","year":"2007","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ccr.2007.02.015","article-title":"The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis","volume":"11","author":"Carrasco","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1365-2141.2007.06742.x","article-title":"Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines","volume":"138","author":"Li","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1182\/blood-2012-03-414920","article-title":"Reconstructing the human hematopoietic niche in immunodeficient mice: Opportunities for studying primary multiple myeloma","volume":"120","author":"Groen","year":"2012","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Schueler, J., Wider, D., Klingner, K., Siegers, G.M., May, A.M., Wasch, R., Fiebig, H.H., and Engelhardt, M. (2013). Intratibial injection of human multiple myeloma cells in NOD\/SCID IL\u20132Rgamma(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079939"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Mirandola, L., Yu, Y., Jenkins, M.R., Chiaramonte, R., Cobos, E., John, C.M., and Chiriva-Internati, M. (2011). Tracking human multiple myeloma xenografts in NOD\u2013Rag\u20131\/IL\u20132 receptor gamma chain-null mice with the novel biomarker AKAP\u20134. BMC. Cancer, 11.","DOI":"10.1186\/1471-2407-11-394"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00223-009-9284-0","article-title":"Correlation of high-resolution X-ray micro-computed tomography with bioluminescence imaging of multiple myeloma growth in a xenograft mouse model","volume":"85","author":"Postnov","year":"2009","journal-title":"Calcif. Tissue Int."},{"key":"ref_49","first-page":"507","article-title":"New strategies for MGUS and smoldering multiple myeloma","volume":"2","author":"Kyle","year":"2004","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lawson, M.A., Paton-Hough, J.M., Evans, H.R., Walker, R.E., Harris, W., Ratnabalan, D., Snowden, J.A., and Chantry, A.D. (2015). NOD\/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119546"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/1097-0142(19850301)55:5<1030::AID-CNCR2820550518>3.0.CO;2-Y","article-title":"Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma","volume":"55","author":"Radl","year":"1985","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.V93.5.1697","article-title":"Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease","volume":"93","author":"Dallas","year":"1999","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/028418600750063587","article-title":"Bisphosphonates--mechanisms of action in multiple myeloma","volume":"39","author":"Shipman","year":"2000","journal-title":"Acta. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4277\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:51:24Z","timestamp":1760165484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":56,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13174277"],"URL":"https:\/\/doi.org\/10.3390\/cancers13174277","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]}}}